The BSH Guidelines Official Podcast

During this podcast, Anna Godfrey discusses the Investigation and management of thrombocytosis without JAK2, CALR or MPL mutations Guideline, published in 2025.

During this podcast, Piers Patten and Renata Walewska discuss the Guideline for the treatment of chronic lymphocytic leukaemia, published in 2025.

During this podcast, Dr Austin Kulasekararaj and Dr Lugain Abdalla discuss the Guidelines for the diagnosis and management of adult aplastic anaemia, published in 2024.

In this episode, Dr Charles Percy discusses the joint British Society for Haematology and United Kingdom Haemophilia Centre Doctors' Organisation Guideline on ' Laboratory investigation and clinical management of acquired coagulation factor inhibitors ', published in 2025. 

Dr Tracey Chan and Dr Dima El-Sharkawi discuss the Updated guidelines for the diagnosis and management of tumour lysis syndrome in adults and children, published in 2025.

Dr Matthew Wilson, Dr Sridhar Chaganti and Dr Wendy Osborne discuss the Clinical management of bispecific antibody therapy for lymphoma Good Practice Paper, published in 2025. 

Dr Eyre is a consultant haematologist specialising in lymphoid malignancies in Oxford.  He has completed an MD Doctorate Thesis in 2017.  He is an investigator on several national lymphoid trials and has published over 170 peer-review articles on lymphoma and CLL.  He is the chair of the low-grade lymphoma clinical trial research group and a core member several lymphoma study groups.  He is a memb...

Podcast recording by James Griffin on the Guideline: Apheresis procedures for the treatment of patients and for the collection of cellular therapy products.

Dr Deepa J. Arachchillage and Dr Jenny Tam present a review of the Guidelines on the investigation and management of antiphospholipid syndrome. Published: 04 August 2025

Dr Matthew Wilson and Dr Kate Cwynarski discuss the Central nervous system prophylaxis in large B-cell lymphoma Good Practice Paper, published in 2024.

Professor Christopher Fox, Dr Sridhar Chaganti and Dr Bernard Maybury discuss the Management of relapsed or refractory large B-cell lymphoma Guideline, published in 2025.

This podcast is the first of a series of three recordings of the Lymphoma Special Interest Group (SIG) Education Session at the 2025 BSH Annual Scientific Meeting.  The Lymphoma SIG is delighted to share talks from three great speakers with the wider audience.   In this recording, Dr David Lewis discusses first-line treatment for mantle cell lymphoma in 2025, focusing on three main themes: 1) the...

Dr Cathy Burton chaired the “Top Abstracts in Lymphoma” session at BSH 2025.  In this episode, she shares with us the highlights from this session.   Dr Burton is a Consultant Haematologist at St James’s University Hospital, Leeds, specializing in Lymphoma and Diagnostics. She is heavily engaged in translational research in lymphoma and is Chair of the Hodgkin lymphoma study group, Deputy Chair of...

Dr Dima El-Sharkawi is a Consultant Haematologist at the Royal Marsden Hospital in Sutton. Her special interests are in CLL, rare leukaemias and lymphomas as well as early phase trials and drug development. She has been an investigator on a number of clinical research studies in these disease groups. She is clinical lead of the Specialist Integrated Haematological Malignancy Diagnostic Services at...

Dr Tracey Chan and Dr Jennifer Pinney discuss the Diagnosis and management of monoclonal gammopathy of renal significance Good Practice Paper, published in January 2025.

In this episode, Dr Sridhar Chaganti shares with us the highlights in large B-cell lymphoma from BSH 2025, including real-world experience in the use of bispecific antibodies and the recent NICE approval of Lisocel as second line treatment.   Dr Chaganti is a Consultant Haemato-oncologist at the University Hospital in Birmingham, with an interest in lymphomas, ALL, stem cell transplantation and im...

Presenters: Sean Platton (Consultant Biomedical Scientist) and Peter Baker (Clinical Scientist and the Laboratory Lead for Haemostasis)   Measurement of heparin, direct oral anti-coagulants and other non-coumarin anti-coagulants and their effects on haemostasis assays: A British Society for Haematology Guideline This guideline aims to update healthcare professionals working in the UK on the measur...

In this episode, Professor Graham Collins shares with us the highlights in Hodgkin lymphoma from BSH 2025.  He takes us through the ECHELON-1 trial, which led to the recent NICE approval of Brentuximab-AVD as a frontline treatment option for advanced stage Hodgkin lymphoma.

Professor Graham Collins discusses the management of primary mediastinal B-cell lymphoma, from initial treatment considerations to the management of relapsed disease.   Professor Collins is a Consultant Haematologist and the lymphoma lead clinician at the Oxford Cancer and Haematology Centre.  He has particular interests in Hodgkin and high-grade non-Hodgkin lymphoma and he chairs the national CAR...

Dr Sridhar Chaganti discusses the use of bispecific T-cell engagers (BITE’s) in large B-cell lymphoma.   Dr Chaganti is a consultant haematologist at University Hospitals Birmingham NHS Foundation Trust. He has a PhD in cancer studies from the University of Birmingham. His research interest is Epstein–Barr virus (EBV) and lymphomas. His special interests are in haematological malignancies, lymphom...

Dr Nikesh (Nik) Chavda discusses supportive care in lymphoma. Dr Chavda is a haematology consultant at University Hospitals Bristol and Weston, with an interest in B-cell malignancies, cellular therapies and histiocytic disorders.

Dr Duncan Murray discusses mycosis fungoides and sezary syndrome. Dr Murray completed his PhD at the University of Birmingham, looking at the interaction between the immune system and malignant T cells in skin lymphoma. He finds the interaction between a "good" and "bad" T cell fascinating. He has used multiple single-cell laboratory techniques to tease apart the two populations (including V-beta...

Dr Matthew Ahearne is a consultant haematologist at University Hospitals of Leicester NHS Trust. His main clinical and research focus is on T-cell lymphomas. Dr Ahearne is Deputy Chair of the  National Cancer Research Institute (NCRI)  T-cell lymphoma working group and an NCRI Lymphoma Science sub-group member.

Dr Sridhar Chaganti discusses the current management of post-transplant lymphoproliferative disorder (PTLD), including subtypes, prognostic factors and the current treatment options. He explores the role of immunotherapy, cytotoxic agents and the emerging field of cellular therapies in this group of patients. Dr Chaganti is a consultant haematologist at University Hospitals Birmingham NHS Foundati...